Research and Development
Effective delivery of BNPs™ to the heart after systemic (intravenous) injection and the therapeutic benefits of DNA-based protein Phosphatase-1 Inhibitor-1 (I-1) delivery to the failing heart have been demonstrated in several proof-of-principle animal studies.
NanoCor has also conducted several failing heart pig studies which demonstrate the therapeutic benefits of I-1 with recombinant adeno-associated virus (rAAV) and the Self-Complementary Vector. The Company is currently conducting several failing heart pig studies with several different candidates of heart tropic BNPs™ to determine the best candidate to advance into human clinical trials.
BNPs™ were used by Asklêpios BioPharmaceutical in a Phase I clinical trial for the treatment of Duchene’s Muscular Dystrophy (DMD), an orphan disease affecting children for which there is currently no life-sustaining treatment.
The self-complementary AAV vector technology used by NanoCor has been validated in a human hemophilia clinical trial demonstrating 100 of sustained therapeutic of factor IX.